Business
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA
About this update from Fortress Biotech, Inc.
[{"type":"image","alt":"Fortress Biotech, Inc.","displaySize":"","headline":null,"caption":"Fortress Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":228,"url":"https://media.zenfs.com/en/globenewswire.com/67d8842b1a3f40249dd9679548ed4862"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3_0qSM501xaK8lgQjQGDIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67d8842b1a3f40249dd9679548ed4862","width":300,"height":228}},"lazy":false},{"type":"text","content":"Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled","length":180,"tagName":"p"},{"type":"text","content":"Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma ","length":213,"tagName":"p"},{"type":"text","content":"FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025","length":136,"tagName":"p"},{"type":"text","content":"MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2024.","length":403,"tagName":"p"},{"type":"text","content":"Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “The fourth quarter of 2024 was transformational for Fortress, marked by two FDA approvals — Emrosi™ and UNLOXCYT™ — as well as the FDAs’ recent acceptance of the New Drug Application for CUTX-101. Additionally, we congratulate Fortress-founded partner company, Checkpoint Therapeutics, Inc. (“Checkpoint”), as earlier this month they signed an exciting agreement that delivers FDA approved UNLOXCYT into the capable and established global commercial organization at Sun Pharma, which is expected to expedite patient access. This transaction is also a successful milestone for Fortres...